Flexible Administration of COVID-19 Vaccines and Therapeutics—A Call for Clarity Around Legality, Liability, and Compensation for Injury

Publication Date

4-2022

Document Type

Article

Organizational Units

Sturm College of Law

Keywords

COVID, Vaccines, Therapeutics, FDA, Emergency use authorization

Abstract

Over the past two years, the Food and Drug Administration (FDA) has approved or issued emergency use authorizations (EUAs) for several interventions intended to prevent or treat COVID-19, including vaccines, monoclonal antibodies, and antiviral medications. These approvals and EUAs are for specific indications, in specific populations, at specific doses, and on specific dosing schedules. However, individuals, clinicians, and state and local governments have often expressed interest in using these COVID-19 interventions outside the parameters specifically approved or authorized by the FDA.

Copyright Date

2022

Copyright Statement / License for Reuse

All Rights Reserved
All Rights Reserved.

Publication Statement

User is responsible for all copyright compliance. This article was originally published as Govind Persad, Patricia J. Zettler & Holly Fernandez Lynch, Flexible Administration of COVID-19 Vaccines and Therapeutics—A Call for Clarity Around Legality, Liability, and Compensation for Injury, Health Affairs Forefront (April 18, 2022), https://www.healthaffairs.org/content/forefront/flexible-administration-covid-19-vaccines-and-therapeutics-clarifying-legality.

Link to Full Text



Share

COinS